Metabolic syndrome in the Pressioni Arteriose Monitorate E Loro Associazioni (PAMELA) study: Daily life blood pressure, cardiac damage, and prognosis

Hypertension

Volumn 49, Issue 1, 2007, Pages 40-47

  Mancia, Giuseppe ^a,b,c,d   Bombelli, Michele ^a   Corrao, Giovanni ^a   Facchetti, Rita ^a   Madotto, Fabiana ^a   Giannattasio, Cristina ^a,b,c,d   Trevano, Fosca Quarti ^a   Grassi, Guido ^a,b,c,d   Zanchetti, Alberto ^a,b,c,d   Sega, Roberto ^a  

^a SAN GERARDO HOSPITAL   (Italy)

^b ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^c UNIVERSITY OF MILANO BICOCCA   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

Author keywords

Blood pressure; Cardiac hypertrophy; Cardiovascular morbidity; Cardiovascular mortality; Metabolic syndrome

Indexed keywords

ADULT; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DATA ANALYSIS; DEATH; ECHOCARDIOGRAPHY; FEMALE; GLUCOSE BLOOD LEVEL; HEART DISEASE; HEART INJURY; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; HYPERTENSION; ITALY; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MORBIDITY; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; AGED; ECHOGRAPHY; HEART RATE; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PREVALENCE; RISK ASSESSMENT;

ADULT; AGED; BLOOD GLUCOSE; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; ECHOCARDIOGRAPHY; FEMALE; HEART RATE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PREVALENCE; PROGNOSIS; RISK ASSESSMENT;

EID: 33847630752     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000251933.22091.24     Document Type: Article

References (41)

1. Ford ES, Giles WH. A comparison of the prevalence of the metabolic syndrome using 2 proposed definitions. Diabetes Care. 2003;26:575-581.
2. Meigs JB, Wilson PW, Nathan DM, D'Agostino RB, Williams K, Haffner SM. Prevalence and characteristics of the metabolic syndrome in the San Antonio Heart and Framingham Offspring Studies. Diabetes. 2003;52:2160-2167.
3. Grundy SM, Brewer HB, Cleeman JI, Smith SC, Lenfant C. Definition of metabolic syndrome: report of the National Heart, Lung and Blood Institute. Circulation. 2004;109:433-438.
4. Hu G, Qiao Q, Tuomilehto J, Balkau B, Borch-Johnsen K, Pyorala KD. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in non diabetic European men and women. Arch Intern Med. 2004;164:1066-1076.
5. Muntner P, He J, Chen J, Fonseca V, Whelton PK. Prevalence of non-traditional cardiovascular disease risk factors among persons with impaired fasting glucose, impaired glucose tolerance, diabetes, and the metabolic syndrome: analysis of the Third National Health and Nutrition Examination Survey (NHANES III). Ann Epidemiol. 2004;14:686-695.
6. Lakka HM, Laaksonen DE, Lakka TA, Niskanene LK, Kumpusalo E, Tuomilehto J, Salonen JT. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;288:2709-2716.
7. Alexander CM, Landsman PB, Teutsch SM, Haffner SM. National Cholesterol Education Program (NCEP). NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes. 2003;52:1210-1214.
8. Sattar N, Gaw A, Scherbakova O, Ford I, O'Reilly DS, Haffner SM, Isles C, Macfarlane PW, Packard CJ, Cobbe SM, Shepherd J. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation. 2003;108:414-419.
9. Ford ES. The metabolic syndrome and mortality from cardiovascular disease and all-causes: findings from the National Health and Nutrition Examination Survey II Mortality Study. Atherosclerosis. 2004;173:309-314.
10. Schillaci G, Pirro M, Vaudo G, Gemelli F, Marchesi S, Porcellati C, Mannarino E. Prognostic value of the metabolic syndrome in essential hypertension. J Am Coll Cardiol. 2004;43:1817-1822.
11. Rutter MK, Meigs GB, Sullivan LM, D'Agostino RB, Wilson PWF. C-reactive protein, the metabolic syndrome and prediction of cardiovascular events in the Framingham offspring study. Circulation. 2004;110:380-385.
12. Girman CJ, Rhodes T, Mercuri M, Pyorala K, Kjekshus J, Pedeersen TR, Beere PA, Gotto AM, Clearfield M. The metabolic syndrome and the risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study. Am J Cardiol. 2004;93:136 -141.
13. Malik S, Wong ND, Franklin SS, Kamath TV, L'Italien GJ, Pio JR, Williams GR. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease and all cause in United States adults. Circulation. 2004;110:1245-1250.
14. McNeill AM, Rosamond WD, Girman CJ, Rosamond WD, Golden SH, Schmidt MI, East HE, Ballantyne CM, Heiss G. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the Atherosclerosis Risk in Communities Study. Diabetes Care. 2005;28:385-390.
15. Dekker JM, Girman C, Rhodes T, Nijpels G, Stehouher CD, Bouter LM, Heine RJ. Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study. Circulation. 2005;112:666-673.
16. Cuspidi C, Meani S, Fusi V, Severgnini B, Valerio C, Catini E, Leonetti G, Magrini F, Zanchetti A. Metabolic syndrome and target organ damage in untreated essential hypertensives. J Hypertens. 2004;22:1991-1998.
17. Leoncini G, Ratto E, Viazzi F, Vaccaio V, Parodi D, Parodi A, Falqui V, Tomilillo C, Deferrari G, Pontremoli R. Metabolic syndrome is associated with early signs of organ damage in non diabetic, hypertensive patients. J Int Med. 2005;257:454-459.
18. Palaniappan L, Carnethon M, Fortmann SP. Association between microalbuminuria and the metabolic syndrome: NHANES III. Am J Hypertens. 2003;16:952-958.
19. Chen J, Muntner P, Hamm LL, Jones DW, Batuman V, Fonseca V, Whelton PK, He J. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med. 2004;140:167-174.
20. Mancia G, Sega R, Bravi C, De Vito G, Valagussa F, Cesana G, Zanchetti A. Ambulatory blood pressure normality: results from the PAMELA Study. J Hypertens. 1995;13:1377-1390.
21. Sega R, Cesana G, Milesi C, Grassi G, Zanchetti A, Mancia G. Ambulatory and home blood pressure normality in the elderly data from the PAMELA population. Hypertension. 1997;30:1-6.
22. Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man. Circulation. 1977;55:613-661.
23. Mancia G, Zanchetti A, Agabiti-Rosei E, Benemio G, De Cesaris R, Fogari R, Pessina A, Porcellati C, Rappelli A, Salvetti A, Trimarco B. Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy. Circulation. 1997;95:1464-1470.
24. Anderson RN, Rosenberg HM. Disease classification: measuring the effect of the Tenth Revision of the International Classification of Diseases on cause-of-death in the United States. Stat Med. 2003;15:1551-1570.
25. Groppelli A, Omboni S, Parati G, Mancia G. Evaluation of non-invasive blood pressure monitoring devices Spacelabs 90202 and 90207 versus resting and ambulatory 24 hour intraarterial blood pressure. Hypertension. 1992;20:227-232.
26. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735-2752.
27. Mancia G, Sega R, Grassi G, Cesana G, Zanchetti A. Defining ambulatory and home blood pressure normality: further considerations based on data from the PAMELA study. J Hypertens. 2001;19:995-999.
28. Chinali M, Devereux RB, Howard BV, Roman MJ, Bella JN, Liu JE, Resnick HE, Lee ET, Best LG, De Simone G. Comparison of cardiac structure and function in american indians with and without the metabolic syndrome. Am J Cardiol. 2004;9:40-44.
29. Grandi AM, Maresca AM, Giudici E, Laurita E, Marchesi C, Solbiati F, Nicolini E, Guasti L, Venco A. Metabolic syndrome and morphofunctional characteristics of the left ventricle in clinically hypertensive nondiabetic subjects. Am J Hypertens. 2006;19:199-205.
30. Oberman A, Prineas RJ, Larson JC, LaCroix A, Lasser NL. Prevalence and determinants of electrocardiographic left ventricular hypertrophy among a multiethnic population of postmenopausal women. Am J Cardiol. 2006;97:512-519.
31. Schillaci G, Pirro M, Pucci G, Mannarino MR, Gemelli F, Siepi D, Vaudo G, Mannarino E. Different impact of the metabolic syndrome on left ventricular structure anf function in hypertensive men and women. Hypertension. 2006;47:881-886.
32. Duerr RL, Huang S, Miraliakbar HR, Clark R, Chien KR, Ross J Jr. Insulin-like growth factor-1 enhances ventricular hypertrophy and function during the onset of experimental cardiac failure. J Clin Invest. 1995;95:619-627.
33. Neri Serneri GG, Boddi M, Modesti PA, Cecioni I, Coppo M, Padeletti L, Michelacci A, Coltella A, Galanti G. Increased cardiac sympathetic activity and insulin-like growth factor-I formation are associated with physiological hypertrophy in athletes. Circ Res. 2001;89:977-982.
34. Grassi G, Seravalle G, Mancia G. Left ventricular hypertrophy and sympathetic activity. Adv Exp Med Biol. 1997;432:173-179.
35. Schlaich MP, Kaye DM, Lambert E, Sommerville M, Socratous F, Esler MD. Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. Circulation. 2003;108:560-565.
36. Mancia G, Carugo S, Grassi G, Lanzarotti A, Schiavina R, Cesana G, Sega R. Prevalence of left ventricular hypertrophy in hypertensive patients without and with blood pressure control: data from the PAMELA population. Hypertension. 2002;39:744-749.
37. ESH-ESC Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology Guidelines for the management of arterial hypertension. J Hypertens. 2003;21:1011-1053.
38. Wannamethee SG, Shaper AG, Lennon L, Morris RW. Metabolic syndrome vs Framingham risk score for prediction of coronary heart disease, stroke and type 2 diabetes mellitus. Arch Intern Med. 2005;165:2644-2650.
39. Alberti KG, Zimmet P, Shaw J. IDF Epidemiology Task Force Consensus Group. The metabolic syndrome-a new worldwide definition. Lancet. 2005;366:1059-1062.
40. Huggett RJ, Burns J, Mackintosh AF, Mary DA. Sympathetic neural activation in nondiabetic metabolic syndrome and its further augmentation by hypertension. Hypertension. 2004;44:847-852.
41. Grassi G, Dell'Oro R, Quarti-Trevano F, Scopelliti F, Seravalle G, Paleari F, Gamba PL, Mancia G. Neuroadrenergic and reflex abnormalities in patients with metabolic syndrome. Diabetologia. 2005;48:1359-1365.